Aptorum, DiamiR Publish Glioblastoma microRNA Biomarker Study with UPenn
Aptorum Group and DiamiR Biosciences published a paper in Diagnostics showing detection of glioblastoma through blood plasma microRNA signatures in collaboration with the University of Pennsylvania. The study identifies specific microRNA biomarkers with potential to replace invasive biopsies and supports expansion of Aptorum’s diagnostics-driven oncology pipeline.
1. Publication Details
Aptorum Group and DiamiR Biosciences released a peer-reviewed paper in Diagnostics titled "Development of microRNA-Based Glioblastoma Biomarkers Using Blood Plasma Specimens". The research was conducted in collaboration with the Perelman School of Medicine at the University of Pennsylvania and marks the first demonstration of GBM detection via blood plasma microRNA signatures.
2. Study Findings
The study identified a set of microRNA signatures in blood plasma that differentiate glioblastoma from control samples, offering a minimally invasive alternative to surgical biopsy and costly imaging. GBM carries a median survival of under 15 months, highlighting the urgent need for earlier detection and improved monitoring tools.
3. Pipeline Implications
These findings validate DiamiR’s microRNA platform and advance Aptorum’s strategy to integrate diagnostics into its oncology pipeline. The non-invasive blood test could accelerate patient screening, support earlier intervention studies, and potentially expand the addressable market for Aptorum.
4. Merger Update
Aptorum and DiamiR entered a definitive all-stock merger agreement in July 2025, pending stockholder approval and customary closing conditions. Completion is expected in the first half of fiscal 2026, after which DiamiR will become a wholly owned subsidiary of Aptorum, bolstering its diagnostic capabilities.